Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Impacts of Total Body Irradiation in Allogeneic Umbilical Cord Blood Hematopoietic Stem Cell Transplantation

Jeffrey J. Pu, Kristin N. Berger, Hao Wang, Wei Fu, Elizabeth L Miller, Larisa Broglie, Heiko Konig, Frederick Goldman, Julie-An Talano, Sherif S. Farag, Melanie Comito

Blood (2021) 138 (Supplement 1): 4852.

https://doi.org/10.1182/blood-2021-152893

Published: 2021

Journal Articles

Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases

Shinya Rai, Lisa M. Hess, Yongmei Chen, Lee Bowman, Paolo B. Abada, Heiko Konig, Richard A. Walgren, Yoshinori Tanizawa, Zhihong Cai, Masaomi Tajimi

Blood (2021) 138 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2021-148265

Published: 2021

Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2019) 134 (Supplement_1): 5051.

https://doi.org/10.1182/blood-2019-124384

Published: 2019

Journal Articles

Integrative Analysis of AML Cell Response to Cytarabine Reveals Synergistic Opportunities Centered on Cholesterol Metabolism

Fangli Chen, MD PhD, Xue Wu, PhD, Rogozea Adriana, Bin Guo, PhD, H. Scott Boswell, MD, George A. Calin, MD PhD, Mircea Ivan, MD PhD, Heiko Konig, MD PhD

Blood (2018) 132 (Supplement 1): 2631.

https://doi.org/10.1182/blood-2018-99-113634

Published: 2018

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Blood (2018) 132 (Supplement 1): 1428.

https://doi.org/10.1182/blood-2018-99-112495

Published: 2018

Journal Articles

A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sonia Christian, MD, Pritesh Patel, MD, Vaibhav Agrawal, MD MBA, Shawn Griffin, PharmD, Kirk Cahill, MD, Irum Khan, MBBS, Karen Sweiss, PharmD, Ardaman Shergill, MD, Gregory Sampang Calip, PharmD,MPH,PhD, Wendy Stock, MD, Olatoyosi Odenike, MD, Heiko Konig, MDPhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2018-99-111389

Published: 2018

Journal Articles

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Vaibhav Agrawal, MD MBA, Jordyn Griffin, MD, Andrew O'Brien, MD, Robert P. Nelson, Jr., MD, Jodi L. Skiles, MD, Heiko Konig, MD PhD

Blood (2018) 132 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2018-99-114189

Published: 2018

Journal Articles

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Blood (2018) 132 (Supplement 1): 4040.

https://doi.org/10.1182/blood-2018-99-112974

Published: 2018

Journal Articles

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Blood (2018) 132 (Supplement 1): 3999.

https://doi.org/10.1182/blood-2018-99-119755

Published: 2018

Journal Articles

Inhibition of Carbonic Anhydrase-IX As a Novel Strategy to Overcome Hypoxia Mediated Drug Resistance in FLT3/ITD Mutated Acute Myeloid Leukemia

Fangli Chen, MD PhD, Adriana Rogozea, George Sandusky, DVM, PhD, Mircea Ivan, MD PhD, Heiko Konig, MDPhD

Blood (2017) 130 (Supplement 1): 2521.

https://doi.org/10.1182/blood.V130.Suppl_1.2521.2521

Published: 2017

Journal Articles

Minimal Intensity Fludarabine/Cyclophosphamide Versus Myeloablative Thiotepa/Cyclophosphamide Followed By Allogeneic Hematopoetic Stem Cell Transplantation (HSCT) for the Treatment of Acute Myeloid Leukemia (AML)— a Retrospective Single Institution Experience

Nabin Khanal, MBBS, Brian E Johnson, MD, H. Scott Boswell, MD, Heiko Konig, MDPhD, Susan M Perkins, PhD, Robert P. Nelson, Jr., MD

Blood (2017) 130 (Supplement 1): 5471.

https://doi.org/10.1182/blood.V130.Suppl_1.5471.5471

Published: 2017

Journal Articles

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Heiko Konig, Mark J. Levis, Alan K. Burnett

Blood (2017) 129 (9): 1143–1154.

https://doi.org/10.1182/blood-2016-07-730648

Published: 2017

Includes: Supplemental data

Journal Articles

Reduced Chemosensitivity of FLT3/ITD Mutated Cells to Cytarabine and Quizartinib Under Hypoxic Conditions

Heiko Konig, MD PhD, Adriana L Rogozea, Garrett H Kinnebrew, MD, Mircea Ivan, MD PhD

Blood (2016) 128 (22): 1579.

https://doi.org/10.1182/blood.V128.22.1579.1579

Published: 2016

Journal Articles

The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells

Edwin Stage, MS, Magdalena Czader, MD PhD, Heather O'Leary, PhD, H. Scott Boswell, MD, Larry D. Cripe, MD, Hamid Sayar, MD, Cedric Dos Santos, PhD, Mark J. Levis, MD PhD, Heiko Konig, MDPhD

Blood (2015) 126 (23): 4928.

https://doi.org/10.1182/blood.V126.23.4928.4928

Published: 2015

Journal Articles

The Combination Of FLT3 Inhibition and Hypomethylation Confers Synergistic Anti-Leukemic Effects On FLT3/ITD Positive AML Cell Lines and Primary Cells

Heiko Konig, MD PhD, Mark Levis, MD, PhD

Blood (2013) 122 (21): 3965.

https://doi.org/10.1182/blood.V122.21.3965.3965

Published: 2013

Journal Articles

The Sal-Like 1 (SALL1) Protein is Highly Expressed in Primary Bone Marrow Cells Derived From Patients with Acute Myeloid Leukemia.

Heiko Konig, MD, PhD, Susan Kiefer, PhD, Lynn Robbins, Michael Rauchman, MD, Huda S. Salman, MD

Blood (2009) 114 (22): 1285.

https://doi.org/10.1182/blood.V114.22.1285.1285

Published: 2009

Journal Articles

The Polyamide-Chlorambucil Conjugate 1R-Chl Effectively Inhibits Proliferation and Induces Apoptosis in CML Progenitor Cells

Heiko Konig, MD, PhD, C. James Chou, PhD, Joel M. Gottesfeld, PhD, Ravi Bhatia, MD

Blood (2008) 112 (11): 5031.

https://doi.org/10.1182/blood.V112.11.5031.5031

Published: 2008

Journal Articles

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606

Heiko Konig, Tessa L. Holyoake, Ravi Bhatia

Blood (2008) 111 (4): 2329–2338.

https://doi.org/10.1182/blood-2007-05-092056

Published: 2008

Journal Articles

MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib.

Paul La Rosee, MD, Nicolai Haertel, MD, Thomas Klag, Heiko Konig, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 652.

https://doi.org/10.1182/blood.V110.11.652.652

Published: 2007

NARROW

Impacts of Total Body Irradiation in Allogeneic Umbilical Cord Blood Hematopoietic Stem Cell Transplantation

Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Integrative Analysis of AML Cell Response to Cytarabine Reveals Synergistic Opportunities Centered on Cholesterol Metabolism

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Inhibition of Carbonic Anhydrase-IX As a Novel Strategy to Overcome Hypoxia Mediated Drug Resistance in FLT3/ITD Mutated Acute Myeloid Leukemia

Minimal Intensity Fludarabine/Cyclophosphamide Versus Myeloablative Thiotepa/Cyclophosphamide Followed By Allogeneic Hematopoetic Stem Cell Transplantation (HSCT) for the Treatment of Acute Myeloid Leukemia (AML)— a Retrospective Single Institution Experience

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Reduced Chemosensitivity of FLT3/ITD Mutated Cells to Cytarabine and Quizartinib Under Hypoxic Conditions

The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells

The Combination Of FLT3 Inhibition and Hypomethylation Confers Synergistic Anti-Leukemic Effects On FLT3/ITD Positive AML Cell Lines and Primary Cells

The Sal-Like 1 (SALL1) Protein is Highly Expressed in Primary Bone Marrow Cells Derived From Patients with Acute Myeloid Leukemia.

The Polyamide-Chlorambucil Conjugate 1R-Chl Effectively Inhibits Proliferation and Induces Apoptosis in CML Progenitor Cells

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606

MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only